Pilot Study of Minocycline in Huntington's Disease

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being conducted to assess the impact of minocycline on the progression of symptoms of HD. The study will also assess whether it is reasonable to continue with further study of minocycline in HD. We will measure the effect of minocycline on HD by measuring the change in Huntington's disease symptoms.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merit Cudkowicz
• Collaborator: FDA Office of Orphan Products Development
• Treatments: Minocycline

Criteria

Inclusion Criteria:

• Age 18 years or older

• Clinical features of HD and a confirmatory family history of HD; and/or genetically confirmed HD

• Independently walking and fully self-sufficient in activities of daily living (eating, dressing, bathing)

• Able to take medication (capsules) by mouth

Exclusion Criteria:

• History of known hypersensitivity or intolerability to minocycline or known allergy to any tetracycline

• History of vestibular disease

• Subjects with underlying hematologic, hepatic or renal disease

• History of systemic lupus erythematosus (SLE)